A Study of Zigakibart in Adults With IgA Nephropathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 383 participants.
Also called NCT05852938
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 383 participants
- Sponsor
- Registry
-
NCT05852938
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, China, Croatia, Czechia, France, Germany, Greece, India, Israel, Italy, Japan, Malaysia, Mexico, South Korea, Spain, Taiwan, Türkiye, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05852938. Randomized; double masking; primary purpose treatment. Start 2023-07-06 (actual); primary completion 2027-08-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Zigakibart in Adults With IgA Nephropathy
- Condition
- IgA Nephropathy
- Condition
- Immunoglobulin A Nephropathy
- Intervention (Drug)
- BION-1301
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct05852938- Content hash
e5cea313809c8a8ab66296f269cb467694c3cefd487c14ee329f7962a2a63491